Financial reports
Current reports
8-K
Completion of Acquisition or Disposition of Assets
16 Mar 23
8-K
Ys Biopharma and Summit Healthcare Announce
14 Mar 23
8-K
Other Events
21 Feb 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7 Feb 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
17 Jan 23
8-K
Entry into a Material Definitive Agreement
29 Sep 22
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
22 Nov 21
8-K
Other Events
27 Jul 21
8-K
Report of Independent Registered Public Accounting Firm
17 Jun 21
8-K
Entry into a Material Definitive Agreement
14 Jun 21
Registration and prospectus
15-12G
Securities registration termination
16 Mar 23
25-NSE
Exchange delisting
16 Mar 23
425
Business combination disclosure
14 Mar 23
425
Business combination disclosure
21 Feb 23
425
Business combination disclosure
8 Feb 23
425
Business combination disclosure
30 Sep 22
425
Business combination disclosure
29 Sep 22
424B4
Prospectus supplement with pricing info
10 Jun 21
8-A12B
Registration of securities on exchange
8 Jun 21
S-1/A
IPO registration (amended)
3 Jun 21
Other
EFFECT
Notice of effectiveness
9 Jun 21
CERT
Certification of approval for exchange listing
8 Jun 21
CORRESP
Correspondence with SEC
4 Jun 21
CORRESP
Correspondence with SEC
4 Jun 21
CORRESP
Correspondence with SEC
3 Jun 21
CORRESP
Correspondence with SEC
3 Jun 21
CORRESP
Correspondence with SEC
3 Jun 21
UPLOAD
Letter from SEC
2 Jun 21
CORRESP
Correspondence with SEC
1 Jun 21
CORRESP
Correspondence with SEC
1 Jun 21
Ownership
4
Bo Tan
21 Mar 23
4
Tao Bai
21 Mar 23
4
Thomas Folinsbee
21 Mar 23
4
Change in insider ownership
21 Mar 23
4
Cho Fai Poon
21 Mar 23
4
Ian Charles Stone
21 Mar 23
SC 13G
GLAZER CAPITAL, LLC
15 Feb 23
SC 13G/A
CANTOR FITZGERALD SECURITIES
15 Feb 23
SC 13G
ARISTEIA CAPITAL LLC
13 Feb 23
SC 13G/A
INTEGRATED CORE STRATEGIES (US) LLC
2 Feb 23